This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Atrium Medical Center.
Recruitment status was:  Recruiting
Information provided by:
Atrium Medical Center Identifier:
First received: September 13, 2005
Last updated: October 29, 2007
Last verified: September 2005
The purpose of this study is to determine which medical treatment is the most effective to terminate a pregnancy.

Condition Intervention Phase
Abortion, Induced Drug: mifepristone Drug: misoprostol Drug: sulprostone Phase 2

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Atrium Medical Center:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female

Inclusion Criteria:

  • Pregnant women by whom a termination of pregnancy is desired.

Exclusion Criteria:

  • Women with liver/kidney disease
  • Women on long-term use of corticosteroids (> 6 months)
  • Cardiovascular problems
  • Therapy-resistant diabetic women
  • Therapy-resistant asthma/bronchitis
  • Thalassemia
  • Ulcerative colitis
  • Peptic ulcer disease
  • Glaucoma
  • Porphyria
  • Allergic reaction to prostaglandin or mifepristone
  • Women with a prior caesarian section or women with contractions at the start of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00206193

Contact: Suzanne HW Vonken, Dr. 003145-5766666 ext 466825
Contact: F Roumen, Dr. 003145-5766666 ext 466509

Atrium Medisch Centrum Recruiting
Heerlen, Limburg, Netherlands
Contact: Suzanne HW Vonken, Dr.    045-5766666(6825)      
Principal Investigator: Suzanne HW Vonken, Dr.         
Sponsors and Collaborators
Atrium Medical Center
Study Director: F Roumen, Dr. Atrium Medisch Centrum, Heerlen
  More Information Identifier: NCT00206193     History of Changes
Other Study ID Numbers: TOP-protocol
Study First Received: September 13, 2005
Last Updated: October 29, 2007

Keywords provided by Atrium Medical Center:
termination of pregnancy

Additional relevant MeSH terms:
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Abortifacient Agents, Steroidal
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents processed this record on August 18, 2017